Vivos Inc (RDGL)

[BottomzUpp]

A contract was signed with University of Missouri to treat
canine sarcomas and equine sarcoids starting early in 2019. The safety review at
UC Davis is almost completed. They will be treating prostate and liver cancer in
canines in 2019.



These animal therapies will generate the additional data required by the private
veterinary clinics to assure them of the safety and efficacy of IsoPet® to
complement the previous work at Washington State University.



The Company anticipates that future profit will be derived from direct sales of
RadioGel™ (under the name IsoPet®) and related services, and from licensing to
private medical and veterinary clinics in the U.S. and internationally.

https://m.marketscreener.com/ADVANCED-MEDICAL-ISOTOPE-14656159/news/VIVOS-Management-s-Discussion-and-Analysis-of-Financial-Condition-and-Results-of-Operations-form-27137322/